Adipocytokines and autoimmunity

By definition, adipo(cyto)kines are cytokine-like mediators produced mainly by adipose tissue. In the human body, they participate in regulating a variety of physiological functions related to energy metabolism [1] and inflammation [2]. Increased or decreased adipokine levels are associated with autoimmune diseases including diabetes mellitus type 1 (DMT1) [3], rheumatoid arthritis (RA) [4,5], ankylosing spondylitis (AS) [6], systemic sclerosis (SSc) [7], systemic lupus erythematosus (SLE) [8] and Behcet's disease [9-12]. 
 
In vitro data suggest that adipokines may contribute to the progression of RA as they are potent inducers of proinflammatory cytokines, chemokines and matrix metalloproteinases (MMP) in RA effector cells [13-16]. 
 
SSc also appears to be associated with adipokines. Contrary to RA, in which substantial intraarticular degradation of extracellular matrix occurs, SSc is characterized by excessive fibrosis. In vitro data and data from animal models of fibrosis point towards a dual role of the adipokine adiponectin as presented by numerous groups at the EULAR congress in London, specifically an antifibrotic effect in later stages of SSc and a profibrotic effect in earlier stages, which appears to be induced by proinflammatory cytokines. Likewise, leptin is involved in the development of liver fibrosis [17-19]. 
 
So far, no or only little functional information is available regarding the role of adipokines in other autoimmune diseases. Serum level and clinical correlation analyses, however, suggest an association with adipokines. 
 
In AS, elevated resistin serum levels have been found, while adiponectin levels remained unchanged [6,20]. On the other hand, leptin is discussed controversially in AS. Serum levels were decreased in AS according to two studies [20,21], while they were increased according to another [22]. Also, while correlations of leptin with parameters of inflammation (C-reactive protein, IL-6) and disease activity (Bath Ankylosing Spondylitis Disease Activity Index) have been found by Park et al. [22], no such correlations could be found by Toussirout et al. [20]. Interestingly, peripheral blood mononuclear cells (PBMC) from AS patients express and secrete more leptin, IL-6 and TNF-α than PBMC from control subjects. Additionally, stimulation of PBMC from AS patients with exogenous leptin led to a significantly increased IL-6 and TNF-α production [23]. Hence, leptin might be involved in the pathogenesis of AS. 
 
In SLE, resistin, for example, has been shown to be associated with general inflammation and bone loss, suggesting a proinflammatory and disease-promoting function [24]. 
 
However, the exact role of adipokines especially in SSc, AS and SLE is still unclear and will require further investigation. Also, further research is warranted to show whether adipokines may represent potential therapeutic targets in this diseases.

Memory T and B lymphocytes and long lived plasma cells represent a repository of the antigenic experience of an individual. By analyzing the specificity and function of these cells we can gain insights into the human immune response and identify mechanisms of protection and immunopathology. We have developed methods to dissect the functional heterogeneity and antigenic repertoire of human T cells, B cells and plasma cells. These methods are used: i) to identify subsets of effector and memory T cells with distinct roles in immune surveillance and protection in different tissues against different classes of pathogens, and ii) to dissect the relative role of plasma cells and memory B cells in the antibody response to pathogens and to isolate broadly neutralizing antibodies. A better understanding of the class and specificity of the human immune response will be instrumental to guide the design of effective vaccines. monospecific TCR transgenic mice we have shown that a short treatment with monoclonal antibodies that block full T cell activation in vivo allows the targeted tissue to itself induce de novo, antigen specific, foxp3 + Treg (iTreg) [1]. We also show that these iTreg are not only concentrated within the target tissue, but are continuously required to suppress the activity of primed effector cells also present within the tissue [2]. When taken together with previous findings of linked suppression and infectious tolerance [3], the evidence suggests that tolerance maintained by iTreg is dependent on a local, tolerogenic microenviroment within the tissue. One component of this microenvironment is the induction, by both innate inflammation and iTreg, of multiple enzymes that consume essential amino acids, including tryptophan, arginine and valine. Local amino acid depletion can be sensed by naïve and effector T cells, via the mammalian target of the immunosuppressive drug rapamycin (mTOR) pathway, which can synergise with TGFβ for the further induction of foxp3 + iTreg [4]. TGFβ is also able to up-regulate the ectoenzymes CD39 and CD73 both on T cells and antigen presenting cells to catabolise inflammatory ATP to anti-inflammatory adenosine [5]. Microarray analysis of tolerated and control skin grafts for patterns of gene expression associated with the tolerogenic microenvironment confirms that these mechanisms are preferentially active locally within the tolerated tissues rather than throughout the systemic lymphoid system. Of particular interest, these same mechanisms seem to be active in grafted syngeneic tissues [6], suggesting that iTreg maintained microenvironments are important for maintaining self tolerance in the face of an inflammatory insult. The challenge now is how we can exploit appropriate combinations of T cell blockade, mTOR inhibition and TGFβ activation for translation to the clinic.  Uncontrolled immune reactions, e.g. in autoimmunity, chronic inflammation or allergy are a major cause of chronic and partially life-threatening diseases. Current treatments including those involving biologics largely rely on unspecific suppression of the effector cells and rarely are able to cure the disease. The native mechanisms of tolerance, notably those of active suppression by regulatory cells, have therefore fascinated immunologists from the beginning on as they promise modulation of the immune system in an antigen-specific way. However, early attempts to achieve tolerance by oral immunization or peptide vaccination worked in mouse models, but hardly were successful in humans. This might have two reasons: a), the modes of tolerogenic vaccination might not be very efficient, and b), the abundance of inflammatory effector/memory cells in adult humans might prevent induction and functioning of regulatory cells.
Our group is presently focusing on the first point and designing novel modifications of peptide-based vaccines able to induce regulatory cells.
Conjugation of peptides to carrier molecules is one way to improve their in vivo efficacy in inducing Foxp3+ Tregs. In an EAE model, an improved protective efficacy can be demonstrated. A second approach is aiming to target the antigen to the gastrointestinal route which is usually associated with tolerization rather than effector response. Use of signal molecules targeting the peptides to epithelial transport mechanisms is presently explored to improve the efficacy of intestinal vaccination. Finally, we investigate immunomodulatory substances produced by parasites for a potential use as tolerogenic adjuvants. While these approaches might help to improve feasibility of peptide vaccination to induce tolerance, we assume that treatment of existing autoimmune disease will require a combination therapy which incorporates elimination of inflammatory effector cells or suppression of their activity. After exposure to alloantigen in vivo and in vitro, alloantigen reactive immunoregulatory activity is enriched in a population of CD4 + T cells that express high levels of CD25, the α chain of the interleukin-2 receptor, and the transcription factor FOXP3. In vivo, common mechanisms underpin the activity of CD25 + CD4 + Treg in adult hosts. We identified a unique role for IFNγ in the functional activity of CD25 + CD4 + alloantigen reactive Treg during the development of operational tolerance to donor alloantigens in vivo that is consistent with observations showing that tolerance to alloantigens cannot be induced in the absence of IFNγ [1]. In order to provide proof of concept data for translation of findings in preclinical models to the bedside, we have demonstrated that human regulatory T cells expanded ex vivo can protect human allografts (skin and vessels) from rejection [2,3]. The identification and characterisation of Treg that can control immune responsiveness to alloantigens has opened up exciting opportunities for new therapies in transplantation.

O5
Relevance and targeting of memory T cells in transplantation Birgit Sawitzki 1,2* , Anja Siepert 3 , Manfred Lehmann 3 , Undine Gerlach 4 , Andreas Pascher 4 , Stefan Tomiuk 5 , Hans-Dieter Volk 1,2 , Petra Reinke 2,6 1 side effects is the most important goal in transplantation medicine. In the last 20 years major progress has been made in understanding the tolerance underlying mechanisms and develop therapeutic strategies in small animal models. However, such knowledge could be rarely translated into the development of successful new therapeutic approaches in clinical transplantation. The success is limited by clinical challenges which are not present in our clean animal facilities such as 1) heterologous immunity -pathogen-specific memory T and B cells recognize alloantigens and boost the immune response towards the allograft, 2) pre-sensitization of recipients -presence of allo-specific memory T and B cells which are inert to most known therapeutic regimens. Thus we know now that we need more personalized treatment strategies according to the patient's immune reactivity. Such a strategy should combine three important aspects: i) an improved immune monitoring; ii) treatment which target memory cells and iii) strategies to reinforce regulation. We have established preclinical transplant models with preformed alloreactive or pathogen-specific memory T cells in which we compare effectiveness of different treatment approaches combining depletional with regulatory approaches. Furthermore, we have performed a DNA microarray screen on samples of transplant patients and identified surface molecules specifically expressed by naïve, central memory, effector memory or terminal differentiated effector memory (TEMRA) T cells. Using this approach we hope to develop antibodies, which specifically deplete effector memory and TEMRA cells but spare naïve and central memory T cells. Such a treatment will be associated with less side effects e.g. infectious complications as compared to global depletion of T and B cells. Haploidentical transplantation, with extensive T cell depletion to prevent GvHD, is associated with a high incidence of infection-related deaths. The key challenge is to improve immune recovery with allogeneic donor T cells without triggering GvHD. As T regulatory cells (Tregs) controlled GvHD in preclinical studies, the present phase I/II clinical trial evaluated the impact of early infusion of donor CD4/CD25+ Tregs, followed by an inoculum of donor mature T cells (Tcons) and positively immunoselected CD34+ cells. Episodes of CMV reactivation were significantly fewer than after our "standard haplo" transplants. In KIR ligand-mismatched transplants, speed of NK cell reconstitution/maturation and size of donor vs recipient alloreactive NK cell repertoires were preserved. In conclusion, in the setting of haploidentical transplantation infusion of Tregs makes administration of a high dose of T cells feasible for the first time. This strategy provides a longterm protection from GvHD and robust immune reconstitution. characterized by excessive fibrosis. In vitro data and data from animal models of fibrosis point towards a dual role of the adipokine adiponectin as presented by numerous groups at the EULAR congress in London, specifically an antifibrotic effect in later stages of SSc and a profibrotic effect in earlier stages, which appears to be induced by proinflammatory cytokines. Likewise, leptin is involved in the development of liver fibrosis [17][18][19]. So far, no or only little functional information is available regarding the role of adipokines in other autoimmune diseases. Serum level and clinical correlation analyses, however, suggest an association with adipokines. In AS, elevated resistin serum levels have been found, while adiponectin levels remained unchanged [6,20]. On the other hand, leptin is discussed controversially in AS. Serum levels were decreased in AS according to two studies [20,21], while they were increased according to another [22]. Also, while correlations of leptin with parameters of inflammation (C-reactive protein, IL-6) and disease activity (Bath Ankylosing Spondylitis Disease Activity Index) have been found by Park et al. [22], no such correlations could be found by Toussirout et al. [20]. Interestingly, peripheral blood mononuclear cells (PBMC) from AS patients express and secrete more leptin, IL-6 and TNF-α than PBMC from control subjects. Additionally, stimulation of PBMC from AS patients with exogenous leptin led to a significantly increased IL-6 and TNF-α production [23]. Hence, leptin might be involved in the pathogenesis of AS. In SLE, resistin, for example, has been shown to be associated with general inflammation and bone loss, suggesting a proinflammatory and disease-promoting function [24]. However, the exact role of adipokines especially in SSc, AS and SLE is still unclear and will require further investigation. Also, further research is warranted to show whether adipokines may represent potential therapeutic targets in this diseases.
Members of a subfamily of the type 1 four-helix-bundle cytokines with receptors sharing the common gamma (c γ ) chain including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 have distinct activities on the differentiation of effector, memory, and regulatory T cells [1,2]. Furthermore, IL-2, IL-4, and IL-21 serve distinct roles in control of B cell development and differentiation to antibody producing cells. We and others recently reported that both IL-2 and IL-21 are essential for maintenance of CD8 T cells and control of chronic viral infection, while both cytokines are dispensable for expansion and contraction of CD8 T cells during acute and resolved viral infection [3][4][5][6][7]. While IL-21 has been implicated in cross-regulation of Th17 cells and inducible regulatory T cells (Treg) in vitro, development of Th17 and Treg cells and consequently organ-related autoimmune disease remain unaffected in IL-21R-deficient mice in vivo [8,9]. In contrast, we now found that IL-21 can potently inhibit proliferation and function of inducible and natural Treg cells in models of T cell transfer colitis, viral infection, and asthma. Increased numbers of Tregs in IL-21R-deficient mice offer an explanation for suppression of Th2-mediated asthma and susceptibility to chronic viral infection described in the knockout mice [5,10]. Furthermore, the importance of IL-21 for B cell and antibody responses has been well established. Recently, it has been suggested that IL-21 is crucial for development of T follicular helper cells (Tfh) and defective B cell responses in IL-21R-deficient mice are due to the absence of Tfh cells. However, we found that germinal center development and antibody responses were severely impaired in mice that lack IL-21R specifically on B cells suggesting that IL-21 regulates germinal center responses in a B cell intrinsic manner [11]. In addition, we have shown that requirement of IL-21 for a B cell response is overcome by immunization with particulate antigens containing TLR7/8 ligands (such as viral RNS). These data demonstrate that innate pathogen patterns (PAMPs) and Th cell derived signals co-operate in the induction of optimal IgG responses. Interestingly, in contrast to follicular B cell responses, IL-21 has been shown to negatively regulate marginal zone (MZ) B-cell survival and antibody production to Streptococous pneumonia [12]. In vivo, the IL-6/soluble IL-6R complex stimulates several types of target cells not stimulated by IL-6 alone, since they do not express the membrane bound IL-6R. This process has been named trans-signaling [1]. We have shown that soluble gp130 is the natural inhibitor of IL-6/soluble IL-6R complex responses. The recombinant soluble gp130 protein is a molecular tool to discriminate between gp130 responses via membrane bound and soluble IL-6R responses. We have constructed a fusion of soluble gp130 and the Fc portion of human IgG1. This sgp130Fc protein proved to be efficient in blocking responses via the IL-6/soluble IL-6R complex without affecting IL-6 responses, which are mediated via the membrane bound IL-6R [1]. The soluble IL-6R is mostly generated by proteolysis of the IL-6R transmembrane protein. Shedding of the IL-6R is mediated by the metalloprotease ADAM17, which is also responsible for the cleavage of TNFα and ligands of the EGF-R. Consequently, activation of ADAM17 has different effects on the activation of the immune response as well as on induction of regenerative responses [2,3]. Interestingly, depending on the animal model used, global blockade of IL-6 signaling by neutralizing monoclonal antibodies and selective blockade of IL-6 trans-signaling can lead to different consequences. We could recently show that inhibition of IL-6 trans-signaling was beneficial in a caecum ligation puncture model whereas global IL-6 blockade showed no benefit in survival of the animals [4]. In contrast, in a sepsis model induced by a bolus injection of LPS, both, global blockade of IL-6 signaling by neutralizing monoclonal antibodies and selective blockade of IL-6 transsignaling proved effective in preventing the death of the animals [5]. Also various infection models suggest a different outcome of global blockade of IL-6 as compared to selective IL-6 trans-signaling inhibition. We could show that the extent of IL-6 trans-signaling in chronic inflammatory diseases and cancer is controlled by the soluble IL-6R. Using the sgp130Fc protein or sgp130Fc transgenic mice we demonstrate that in several chronic inflammatory diseases and cancers including inflammatory bowel disease, peritonitis, rheumatoid arthritis, colon cancer, ovarian cancer and pancreatic cancer, that IL-6 trans-signaling via the soluble IL-6R is a crucial step in the development and the progression of the disease. Therefore, sgp130Fc is a novel therapeutic agent for the treatment of chronic inflammatory diseases and cancer [1,[6][7][8].
means that while expression of the cytokine genes upon primary instruction requires signals from both, the T cell receptor and receptors for instructing cytokines, reexpression requires only T cell receptor signaling in reactivated effector/memory T cells. Interleukin-12 (IL-12 A hallmark of immunity is the production of a multi-faceted array of inflammatory cytokines that exerts decisive influence on innate and adaptive immune responses. The importance of these mediators of intercellular communication in autoimmunity is illustrated by the beneficial effects resulting from blockade of single cytokines such as TNF or IL-6 in these diseases. B lymphocytes can also play pathogenic roles during autoimmune disease because B cell depletion often led to amelioration of disease in patients treated with rituximab [1]. The pathogenic functions of B cells during autoimmune diseases are poorly understood. They might involve autoantibody production, yet the beneficial effects resulting from the depletion of B cells usually preceded reduction in autoantibody titers [2]. We recently demonstrated that the pathogenic activities of B cells during experimental autoimmune encephalomyelitis (EAE), the primary animal model for multiple sclerosis (MS), were largely mediated through provision of inflammatory cytokines. B cells from MS patients also produced enhanced amounts of inflammatory cytokines, compared to B cells from healthy individuals, and this abnormality was corrected through B cell depletion i.e. B cells returning at 1 year after rituximab treatment showed a normalized cytokine response. Inflammatory processes are usually balanced by counter-regulatory circuits involving anti-inflammatory cytokines such as interleukin (IL)-10 [3,4]. We previously demonstrated that IL-10 production by B lymphocytes played a determinant role for the resolution of EAE [5]. Accordingly, IL-10 might provide a powerful means for controlling pathogenic immune reactions. However, administration of IL-10 into patients achieved little beneficial effects in the clinic, asking for a better understanding of the immunosuppressive biology of this molecule.
To this end, we pursued the characterization of IL-10-producing B cells in a model of infection by the intracellular bacterial pathogen Salmonella typhimurium. Using a novel strain of IL-10.eGFP knock-in mice to facilitate the tracking of these cells, we could identify IL-10 producing B cells already within 24 hours after infection in spleen, and demonstrated that all IL-10 + B cells expressed the cell surface receptor CD138, which is a distinctive marker of antibody secreting cells [6,7]. IL-10 expression was undetectable in other cell types such as dendritic cells, macrophages, or T cells at this stage, implying that plasmablasts were the first producers of IL-10 during immune reactions. These data suggest that IL-10 might be needed at a very early stage of immune reactions to be suppressive. Collectively, our data showed that B cells have a dual role during autoimmune diseases, acting both as drivers and regulators of pathogenesis, and identified cytokine production as core mechanisms in these complex functions.
transfected cells or peripheral mononuclear blood cells. However, the extracellular functionality of IL-37 is still elusive. The prototypic autoimmune disease, systemic lupus erythematosus (SLE), is known to be associated with polyclonal B cell activation [1]. A number of cytokines play essential roles in driving or supporting B cell responses, and are, therefore, candidate targets for controlling the B cell activity in SLE. Among these cytokines are IL-6, IL-21 and BAFF/BLyS. IL-6 is a pleiotropic cytokine with effects on a number of cell types, including B cells, where it plays as essential role in plasma cell differentiation and survival. Blocking IL-6 activity with tocilizumab is approved for treatment of rheumatoid arthritis and preliminary data suggest that it might also be effective in the treatment of SLE [2]. Importantly, treatment of SLE is associated with a decline in anti-DNA antibodies and also a decrease in the frequency of circulating plasma cells, suggesting that at least part of its action relates to an impact on terminal differentiation of B cells into plasma cells. IL-21 is a type I cytokine with effects on a number of cell types, including a nonredundant requirement in B cell activation and differentiation into plasma cells [3]. Levels of IL-21 are elevated in a number of animal models of lupus and also in human SLE. Blocking IL-21 is effective in animal models of lupus, whereas polymorphisms in both the IL-21 gene and in the IL-21 receptor gene are associated with human SLE. Trials of blocking IL-21 in human SLE have not yet begun. BAFF/BLyS(TNFSF13b) is a TNF family member that binds to 3 separate receptors and contributes to both naïve B cell and plasma cell survival [4]. Overexpression of BAFF/BLyS in mice leads to a lupus-like disorder, whereas blocking this cytokine ameliorates lupus in mouse models. Clinical trials in human SLE of a blocking monoclonal antibody, belimumab, have shown moderate clinical benefit associated with decreases in anti-DNA antibody titers and a decrease in circulating naïve B cells and plasma cells. These results led to the approval of this product for the treatment of SLE in the US. The approval of belimumab for treatment of SLE has confirmed that targeting B cells can be effective in treating this disease and has provided impetus for the development of additional B cell-directed therapies aimed at blocking cytokines involved in B cell survival and/or functional responsiveness.